Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) - Pipeline Review, H1 2016
Summary
Global Markets Direct’s, ‘Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) - Pipeline Review, H1 2016’, provides in depth analysis on Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) targeted pipeline therapeutics.
The report provides comprehensive information on the Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) targeted therapeutics development and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein)
- The report reviews Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) targeted therapeutics and enlists all their major and minor projects
- The report assesses Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table Of Contents
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) Overview 7
Therapeutics Development 8
Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) - Products under Development by Stage of Development 8
Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) - Products under Development by Therapy Area 9
Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) - Products under Development by Indication 10
Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) - Pipeline Products Glance 11
Late Stage Products 11
Early Stage Products 12
Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) - Products under Development by Companies 13
Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) - Therapeutics Assessment 15
Assessment by Monotherapy/Combination Products 15
Assessment by Mechanism of Action 16
Assessment by Route of Administration 17
Assessment by Molecule Type 19
Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) - Companies Involved in Therapeutics Development 21
Alteogen Inc. 21
Chengdu Kanghong Pharmaceuticals Group Co., Ltd. 22
Clearside BioMedical, Inc. 23
Formycon AG 24
Regeneron Pharmaceuticals, Inc. 25
Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) - Drug Profiles 26
(aflibercept + nesvacumab) - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
(aflibercept + rinucumab) - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
(aflibercept + triamcinolone acetonide) - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
aflibercept - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
aflibercept biosimilar - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
aflibercept biosimilar - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
conbercept - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
SL-002 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
SL-186 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
SL-188 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
THR-317 - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
ziv-aflibercept (recombinant) - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) - Dormant Projects 57
Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) - Discontinued Products 58
Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) - Featured News & Press Releases 59
Jun 08, 2016: NICE draft recommendation on the use of aflibercept (EYLEA) for management of branch retinal vein occlusion goes against Royal College of Ophthalmologists’ guidance 59
May 02, 2016: Oncurious NV, BioInvent and NMTRC Initiating Phase I/IIa Study with TB-403 for the Treatment of Medulloblastoma 60
Apr 26, 2016: Clearside Biomedical Announces Positive Preliminary Phase 2 Results in Patients With Macular Edema Associated with Retinal Vein Occlusion 61
Mar 15, 2016: BioInvent and Oncurious Partner with US Research Consortium to Accelerate Phase I/IIa Trial of TB-403 61
Mar 01, 2016: Aflibercept in myopic choroidal neovascularization: Added benefit not proven 62
Feb 29, 2016: Formycon discloses details on second pipeline product - FYB203 is a biosimilar for Eylea (aflibercept) 63
Jan 07, 2016: BioInvent announces FDA acceptance of the Investigational New Drug application for the phase I/IIa study with TB-403 63
Dec 14, 2015: Clearside Biomedical Completes Enrollment in Phase 2 Clinical Trial of CLS-TA for the Treatment of Retinal Vein Occlusion Using Suprachoroidal Space Drug Administration 64
Oct 30, 2015: Bayer Receives EU Approval for EYLEA for the Treatment of Visual Impairment Secondary to Myopic Choroidal Neovascularization 65
Sep 25, 2015: Bayer’s Eye Drug Recommended for EU Approval in Fifth Indication 65
Sep 18, 2015: Three-Year Results with EYLEA Show Sustained Improvement in Vision for People with Diabetic Macular Edema 66
Jul 21, 2015: NICE gives green light to aflibercept solution for treating serious eye condition 67
Jun 26, 2015: Bayer Receives Approval for EYLEA for the Treatment of Retinal Vein Occlusion in Japan 67
Jun 02, 2015: NICE Recommended Aflibercept Solution For Injection For Treating Serious Diabetic Eye Condition In Final Draft Guidance 68
May 06, 2015: Data presented at ARVO 2015 further showcase the real-world efficacy of EYLEA in UK clinical practice 68
Appendix 71
Methodology 71
Coverage 71
Secondary Research 71
Primary Research 71
Expert Panel Validation 71
Contact Us 71
Disclaimer 72
List Of Tables
List of Tables
Number of Products under Development for, H1 2016 8
Number of Products under Development by Therapy Area, H1 2016 9
Number of Products under Development by Indication, H1 2016 10
Comparative Analysis by Late Stage Development, H1 2016 11
Comparative Analysis by Early Stage Products, H1 2016 12
Number of Products under Development by Companies, H1 2016 13
Products under Development by Companies, H1 2016 14
Assessment by Monotherapy/Combination Products, H1 2016 15
Number of Products by Stage and Mechanism of Action, H1 2016 16
Number of Products by Stage and Route of Administration, H1 2016 18
Number of Products by Stage and Molecule Type, H1 2016 20
Pipeline by Alteogen Inc., H1 2016 21
Pipeline by Chengdu Kanghong Pharmaceuticals Group Co., Ltd., H1 2016 22
Pipeline by Clearside BioMedical, Inc., H1 2016 23
Pipeline by Formycon AG, H1 2016 24
Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016 25
Dormant Projects, H1 2016 57
Discontinued Products, H1 2016 58
Lisst Of Figures
List of Figures
Number of Products under Development for, H1 2016 8
Number of Products under Development by Therapy Area, H1 2016 9
Number of Products under Development by Indication, H1 2016 10
Comparative Analysis by Late Stage Development, H1 2016 11
Comparative Analysis by Early Stage Products, H1 2016 12
Assessment by Monotherapy/Combination Products, H1 2016 15
Number of Products by Stage and Mechanism of Actions, H1 2016 16
Number of Products by Routes of Administration, H1 2016 17
Number of Products by Stage and Routes of Administration, H1 2016 17
Number of Products by Molecule Types, H1 2016 19
Number of Products by Stage and Molecule Type, H1 2016 19
